Currently Viewing:
Evidence-Based Oncology July 2017
Daratumumab With Standard Regimen Improves PFS, ORR Independent of Cytogenetic Risk in Multiple Myeloma
Surabhi Dangi-Garimella, PhD
Currently Reading
Phase 1 Study Results at ASCO Support First-Line Use of Daratumumab in Multiple Myeloma
Surabhi Dangi-Garimella, PhD
Patient Selection Vital in Ensuring Improved Response to PD-1, PD-L1 Inhibitors in NSCLC
Surabhi Dangi-Garimella, PhD
An Early Stage Safety, Efficacy Study for Atezolizumab Plus Daratumumab in Advanced NSCLC
Surabhi Dangi-Garimella, PhD
LDH Levels Could Predict irAEs Associated With Checkpoint Inhibition and Radiotherapy in Lung Cancer
Surabhi Dangi-Garimella, PhD
Alectinib May Be a New Standard of Care for Treatment-Naïve ALK-Positive NSCLC
AJMC Staff
Dacomitinib a New First-Line Option for Advanced EGFR MutationŚPositive NSCLC
AJMC Staff
Androgen Deprivation, With or Without Radiotherapy, New Standard of Care in High-Risk Prostate Cancer
AJMC Staff
Trabectedin and Lurbinectedin Effective in BRCA2-Associated Metastatic Breast Cancer
AJMC Staff
HPV Vaccination May Lower Prevalence of Oropharyngeal Cancers in Young Adults
Surabhi Dangi-Garimella, PhD
Physical Activity, Healthy Diet Improve Survival in Colorectal Cancer: Study at ASCO
Surabhi Dangi-Garimella, PhD
Three Months of Oxaliplatin-Based Adjuvant Therapy Noninferior to 6 Months in Stage III Colon Cancer
AJMC Staff
Fas Biomarker Can Predict Response to Second-Line Therapy for Advanced Soft Tissue Sarcoma
AJMC Staff
Nivolumab, Alone or With Ipilimumab, Met the Disease Control Rate in Malignant Pleural Mesothelioma
AJMC Staff
Ibrutinib vs No Consolidation Are Being Compared Following Autologous HSCT in IRONCLAD Trial
AJMC Staff
Web-Based Patient Reporting of Symptoms Shown to Improve Survival in Patients With Metastatic Solid Tumors
AJMC Staff
Physician, Regulatory, and Payer Perspectives on the Value of Real-World Data
Surabhi Dangi-Garimella, PhD
Do We Have Adequate Surveillance in Cancer Care?
Surabhi Dangi-Garimella, PhD
MACRA 2.0 and Beyond: Preparing Your Practice to Meet the Quality and Reporting Challenges
Surabhi Dangi-Garimella, PhD
ASCO Study Finds Shift in Diagnosis Stage for Several Cancers Following ACA Implementation
Surabhi Dangi-Garimella, PhD
Switching Study Reports Equivalence Between Filgrastim, Biosimilar in Breast Cancer
Surabhi Dangi-Garimella, PhD
Research Demonstrates Efficacy and Safety of Trastuzumab Biosimilar SB3
Kelly Davio
CT-P6, a Trastuzumab Biosimilar, Shares the Safety and Efficacy Profile of Its Reference
Kelly Davio
Can the 4 Ps Devise Interventions to Reduce the Financial Toxicity of Cancer?
Surabhi Dangi-Garimella, PhD
Adjuvant Chemotherapy Reduces Cost, Improves Survival in NSCLC Post-Surgery
Surabhi Dangi-Garimella, PhD
Brazilian Study Queries: Is NGS Cost-Effective in Advanced Lung Cancer?
Surabhi Dangi-Garimella, PhD
SEER-Medicare Database Analysis Notes Higher Resource Utilization Among Patients With Neuroendocrine Tumors
Surabhi Dangi-Garimella, PhD

Phase 1 Study Results at ASCO Support First-Line Use of Daratumumab in Multiple Myeloma

Surabhi Dangi-Garimella, PhD
A phase 1 study, presented at the 2017 Annual Meeting of the American Society of Clinical Oncology, found that using daratumumab, an antibody that binds and inhibits the CD38 receptor, can improve patient response to treatment.
A COMBINATION OF PROTEASOME inhibitors and immunomodulatory drugs in the standard of care has improved outcomes in patients with multiple myeloma over the past 10 years. However, these patients can relapse even after complete remission in first-line indications. A phase 1 study, presented at the 2017 Annual Meeting of the American Society of Clinical Oncology, found that using daratumumab, an antibody that binds and inhibits the CD38 receptor, can improve patient response to treatment.

The trial enrolled newly diagnosed patients, regardless of transplantation eligibility. Patients were administered daratumumab at 16 mg/kg weekly for cycles 1 and 2, every other week for cycles 3 to 6, and once in 4 weeks thereafter. Carfilzomib was administered on days 1, 8, and 15 of each 28-day cycle (20 mg/m2 on day 1 of cycle 1 and 36 mg/m2 or 70 mg/m2 based on tolerability of first dose), for most of the 13 cycles, or treatment was discontinued for allogenic stem cell transplant. The treatment also included 25-mg lenalidomide given on days 1 to 21 and dexamethasone 20 to 40 mg weekly. The primary endpoint for this very early phase trial was tolerability.

Twenty-two patients received a median of 8 (range, 1-10) treatment cycles and were followed for a median of 7.4 months (range, 4.0-9.3). Six patients (27%) discontinued treatment, with serious adverse events (AEs) observed in 46% of patients, 14% of which were thought to be related to daratumumab. Grade 3/4 treatment-emergent AEs (TEAE) were observed in 18 (82%) patients: lymphopenia (50%) and neutropenia (23%) were most common. No grade 5 TEAEs were reported.

The authors concluded that daratumumab with carfilzomib and lenalidomide was well tolerated, consistent with results previously reported for carfilzomib plus lenalidomide, with no additional toxicity observed. They claimed that daratumumab can be a feasible option for induction therapy in newly diagnosed patients with multiple myeloma. No grade 3/4 toxicities were noted. The treatment was highly effective, with a 100% overall response rate as well as a 100% 6-month progression-free survival. The depth of response improved with treatment duration.
REFERENCE

Jakubowiak AJ, Chari A, Lonial S, et al. Daratumumab (DARA) in combination with carfilzomib, lenalidomide, and dexamethasone (KRd) in patients (pts) with newly diagnosed multiple myeloma (MMY1001): an open-label, phase 1b study. J Clin Oncol. 2017;35(suppl; abst 8000).
PDF
 
Copyright AJMC 2006-2017 Clinical Care Targeted Communications Group, LLC. All Rights Reserved.
x
Welcome the the new and improved AJMC.com, the premier managed market network. Tell us about yourself so that we can serve you better.
Sign Up
×

Sign In

Not a member? Sign up now!